Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly shorten bexotegrast’s time...
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc....
A review of Russian and English literature suggests that Appili’s biodefense program ATI-1701 may have a role in preventing tularemia...
TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM), a clinical-stage life science biotechnology company pioneering the...
Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation Recently completed meetings with U.S. Food...
LA JOLLA, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on...
Program honors women executives who influence care delivery and policyNatchitoches, Louisiana--(Newsfile Corp. - March 11, 2024) - Liviniti is proud...
Financing expected to fund strategic expansion of obesity clinical development and extend operating runway beyond 2026San Diego, California--(Newsfile Corp. -...
TORONTO, ON / ACCESSWIRE / March 11, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Whittier's Annual Roast to Toast Fundraiser on April 3rd, 2024 Will Support Health and Social Services for Boston's Most Vulnerable...
Long-term extension (LTE) FRONTIER 2 study demonstrated sustained efficacy and similar safety results from Week 16 to Week 52, consistent...
ZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signatureSuggests skin barrier disruption in...
– STRIDE Phase 2 primary endpoint of PASI 75 and key secondary endpoints met at all clinically relevant doses tested;...
Interchangeability study for HADLIMA (adalimumab-bwwd) was conducted in accordance with the FDA’s Guidance for Industry; primary pharmacokinetics (PK) endpoints as...
Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024Advancing VELDONA drug candidates to Phase III clinical studiesExpanding...
BOHEMIA, NY / ACCESSWIRE / March 8, 2024 / Scientific Industries, Inc. ("SI") (OTCQB:SCND) announced the appointment of John Nicols...
Toronto, Ontario--(Newsfile Corp. - March 8, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light...
WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of...